influenza
virus
caus
annual
season
epidem
occasion
pandem
human
respiratori
diseas
influenza
viru
infect
repres
seriou
public
health
econom
problem
effect
prevent
vaccin
howev
influenza
virus
undergo
continu
antigen
variat
requir
either
annual
reformul
season
influenza
vaccin
rapid
gener
vaccin
potenti
pandem
viru
strain
segment
natur
influenza
viru
allow
reassort
two
virus
within
coinfect
cell
characterist
also
har
laboratori
gener
reassort
virus
use
either
inactiv
liveattenu
influenza
vaccin
implement
plasmidbas
revers
genet
techniqu
possibl
engin
recombin
influenza
virus
entir
fulllength
complementari
dna
copi
viral
genom
transfect
suscept
cell
revers
genet
system
provid
investig
novel
power
approach
answer
import
question
biolog
influenza
virus
includ
function
viral
protein
interact
cellular
host
factor
mechan
influenza
viru
transmiss
pathogenesi
addit
revers
genet
techniqu
allow
gener
recombin
influenza
virus
provid
power
technolog
develop
inactiv
liveattenu
influenza
vaccin
review
summar
current
knowledg
stateoftheart
plasmidbas
influenza
revers
genet
approach
implement
provid
rapid
conveni
safe
effect
influenza
inactiv
liveattenu
vaccin
trimer
complex
consist
polymeras
basic
acid
pa
protein
togeth
viral
np
minim
compon
involv
viral
replic
transcript
figur
virion
structur
iav
ibv
b
iav
ibv
surround
lipid
bilay
contain
two
viral
glycoprotein
hemagglutinin
ha
respons
bind
sialic
acidcontain
receptor
surfac
suscept
cell
neuraminidas
na
respons
viral
releas
infect
cell
furthermor
virion
membran
ion
channel
iav
nb
ibv
protein
viral
lipid
bilay
protein
layer
compos
protein
play
role
virion
assembl
bud
nuclear
export
protein
nep
involv
nuclear
export
viral
ribonucleoprotein
vrnp
complex
eight
viral
segment
protein
product
indic
insid
virion
black
line
end
eight
iav
ibv
vrna
indic
noncod
region
ncr
polymeras
basic
pa
polymeras
acid
np
nucleoprotein
ns
nonstructur
gene
matrix
influenza
b
matrix
protein
influenza
iav
b
ibv
virus
belong
orthomyxovirida
famili
envelop
virus
iav
abl
infect
sever
speci
mostli
exist
wild
aquat
fowl
reservoir
hand
ibv
mainli
restrict
adapt
human
although
sporad
infect
seal
document
iav
ibv
genom
contain
eight
neg
sens
singlestrand
viral
v
rna
segment
figur
iav
ibv
vrna
contain
central
code
region
flank
termin
end
noncod
region
ncr
serv
promot
initi
genom
replic
gene
transcript
viral
polymeras
complex
influenza
vrna
virion
found
viral
ribonucleoprotein
vrnp
complex
encapsid
viral
nucleoprotein
np
singl
copi
viral
polymeras
complex
influenza
virusencod
rnadepend
rna
polymeras
rdrp
trimer
complex
consist
polymeras
basic
acid
pa
protein
togeth
viral
np
minim
compon
involv
viral
replic
transcript
iav
ibv
share
mani
featur
differ
host
rang
virion
structur
genom
organ
glycan
bind
specif
despit
similar
genom
encod
homolog
protein
iav
ibv
distinguish
differ
length
protein
noncod
region
ncr
serv
promot
genom
replic
gene
transcript
figur
likewis
also
distinguish
presenc
accessori
protein
encod
overlap
open
read
frame
orf
antigen
differ
intern
protein
figur
b
instanc
iav
ibv
encod
ion
channel
protein
gene
segment
respect
protein
iav
ibv
encod
togeth
matrix
protein
incorpor
virion
express
surfac
virusinfect
cell
howev
protein
iav
translat
splice
mrna
ibv
protein
translat
use
differ
strategi
initi
codon
protein
overlap
termin
codon
protein
uaaug
stopstart
pentanucleotid
addit
ibv
express
nb
ion
channel
absent
type
influenza
viru
figur
howev
influenza
virus
encod
two
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
figur
b
iav
ibv
ha
protein
involv
bind
cellular
receptor
respons
fusion
viral
endosom
membran
infect
iav
ibv
induc
protect
immun
mediat
least
partial
antibodi
direct
viral
ha
main
immunogen
target
natur
infect
vaccin
approach
influenza
na
glycoprotein
respons
cleavag
sialic
acid
moieti
iav
ibv
share
mani
featur
differ
host
rang
virion
structur
genom
organ
glycan
bind
specif
despit
similar
genom
encod
homolog
protein
iav
ibv
distinguish
differ
length
protein
noncod
region
ncr
serv
promot
genom
replic
gene
transcript
figur
likewis
also
distinguish
presenc
accessori
protein
encod
overlap
open
read
frame
orf
antigen
differ
intern
protein
figur
b
instanc
iav
ibv
encod
ion
channel
protein
gene
segment
respect
protein
iav
ibv
encod
togeth
matrix
protein
incorpor
virion
express
surfac
virusinfect
cell
howev
protein
iav
translat
splice
mrna
ibv
protein
translat
use
differ
strategi
initi
codon
protein
overlap
termin
codon
protein
uaaug
stopstart
pentanucleotid
addit
ibv
express
nb
ion
channel
absent
type
influenza
viru
figur
howev
influenza
virus
encod
two
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
figur
b
iav
ibv
ha
protein
involv
bind
cellular
receptor
respons
fusion
viral
endosom
membran
infect
iav
ibv
induc
protect
immun
mediat
least
partial
antibodi
direct
viral
ha
main
immunogen
target
natur
infect
vaccin
approach
influenza
na
glycoprotein
respons
cleavag
sialic
acid
moieti
sialyloligosaccharid
facilit
releas
newli
produc
virion
infect
cell
iav
classifi
basi
antigen
properti
ha
na
ha
na
subtyp
howev
iav
subtyp
current
circul
human
hand
two
major
lineag
ibv
circul
human
victorialik
yamagatalik
subtyp
diverg
ancestr
ibv
cocircul
human
sinc
two
subtyp
predomin
circul
viru
strain
everi
three
year
infect
influenza
virus
begin
viral
ha
protein
bind
cellular
receptor
sialyl
glycoprotein
contain
linkag
upon
bind
receptor
uptak
viru
receptormedi
endocytosi
initi
cell
membran
engulf
viru
particl
endosom
endocytosi
upon
acidif
endosom
influenza
viral
ha
undergo
conform
chang
respons
fusion
viral
endosom
membran
iav
ibv
ion
channel
protein
promot
releas
vrnp
complex
virion
core
cytoplasm
infect
cell
vrnp
transloc
cytoplasm
nucleu
infect
cell
initi
viral
genom
replic
gene
transcript
nuclear
export
nep
matrix
protein
respons
nuclear
export
newlysynthes
vrnp
cytoplasm
infect
cell
notabl
singl
copi
eight
vrna
packag
new
virion
select
packag
influenza
vrna
nascent
virion
mediat
rnarna
interact
vrna
packag
signal
present
termin
end
vrna
segment
final
receptordestroy
enzymat
activ
na
respons
releas
newlysynthes
viral
particl
surfac
infect
cell
among
first
battl
host
viru
cellular
type
interferon
ifni
play
import
role
control
viral
infect
therefor
virus
develop
multipl
strategi
hijack
host
cellular
immun
respons
influenza
vrna
segment
nonstructur
ns
gene
encod
two
distinct
protein
direct
altern
splice
mechan
influenza
viru
segment
produc
nonstructur
protein
primari
transcript
wherea
nep
produc
altern
splice
ns
mrna
multipl
function
replic
cycl
influenza
viru
notabl
inhibit
induct
ifni
respons
innat
immun
activ
influenza
virus
pose
threat
human
health
respons
global
epidem
everi
year
fact
influenza
viru
one
signific
caus
morbid
mortal
yearli
lead
signific
econom
impact
despit
implement
effect
comprehens
vaccin
program
world
health
organ
estim
season
influenza
viru
infect
result
one
billion
infect
million
case
sever
diseas
death
around
world
annual
moreov
unit
state
us
influenza
viral
infect
result
averag
billion
dollar
cost
due
prophylact
therapeut
hospit
cost
well
miss
school
work
day
addit
season
influenza
iav
caus
sporad
pandem
great
consequ
novel
virus
introduc
human
mechan
respons
emerg
season
pandem
iav
antigen
drift
antigen
shift
respect
case
season
influenza
mutat
viral
genom
result
select
antigen
variant
chang
viral
tropism
increas
level
viral
fit
abil
escap
neutral
antibodi
nab
respons
induc
upon
previou
natur
infect
vaccin
moreov
antigen
drift
lead
variant
virus
resist
antivir
contrari
antigen
shift
result
coinfect
host
cell
organ
two
iav
vrna
viral
progeni
reassort
obtain
viral
segment
constel
confer
influenza
viru
optim
replic
transmiss
immunolog
escap
reassort
iav
lead
pandem
immunologicallyna
popul
iav
ibv
reassort
intratyp
subtyp
lineag
intertyp
reassort
genet
swap
segment
iav
ibv
report
absenc
intertyp
reassort
mediat
lack
compat
packag
signal
iav
ibv
last
centuri
three
iav
pandem
occur
spanish
flu
asian
flu
hong
kong
flu
three
spanish
flu
particularli
fatal
respons
approxim
million
death
around
world
although
classifi
true
pandem
three
epidem
influenza
virus
fear
pandem
potenti
swineorigin
iav
respons
first
influenza
pandem
centuri
infect
less
one
year
individu
around
world
although
influenza
viru
infect
primarili
spread
persontoperson
transmiss
via
aerosol
droplet
infect
new
avianor
swineorigin
iav
take
place
may
great
risk
pandem
potenti
viru
acquir
abil
transmit
human
ibv
usual
contribut
less
season
epidem
iav
subtyp
contribut
type
influenza
strain
predomin
circul
viru
strain
everi
three
year
moreov
last
decad
ibv
caus
sever
acut
respiratori
ill
outbreak
date
influenza
pandem
link
ibv
public
health
concern
pose
influenza
viru
infect
aggrav
abil
influenza
virus
effici
transmit
limit
therapeut
option
treat
viral
infect
thu
vaccin
remain
best
medic
intervent
protect
human
season
influenza
viru
howev
effici
current
influenza
vaccin
suboptim
segment
genom
influenza
virus
provid
evolutionari
advantag
reassort
exchang
viral
genom
segment
differ
viral
strain
within
type
addit
exchang
genom
materi
antigen
shift
influenza
virus
introduc
mutat
genom
antigen
drift
lead
viral
mutant
resist
current
antivir
nab
antigen
drift
influenza
vaccin
need
reformul
yearli
ensur
ha
na
present
vaccin
match
present
circul
season
virus
date
three
type
influenza
viru
vaccin
approv
food
drug
administr
fda
human
use
recombin
viral
ha
inactiv
viru
liveattenu
virus
regardless
type
vaccin
season
influenza
vaccin
contain
antigen
three
circul
influenza
viru
strain
iav
subtyp
ibv
victorialik
yamagatalik
lineag
recent
improv
efficaci
season
influenza
vaccin
quadrival
influenza
vaccin
formul
includ
ibv
lineag
compon
victorialik
yamagatalik
lineag
approv
fda
common
influenza
vaccin
inactiv
influenza
vaccin
iiv
iiv
administ
intramuscularli
shown
elicit
protect
humor
immun
produc
nab
target
epitop
ha
contrast
iiv
liveattenu
influenza
vaccin
laiv
administr
mimic
natur
rout
viru
infect
consequ
risk
benefit
advantag
laiv
elicit
rapid
effici
innat
adapt
immun
respons
provid
effici
crossreact
tcellmedi
protect
heterolog
influenza
virus
although
iiv
laiv
shown
effici
treatment
influenza
viral
infect
unmet
need
increas
effect
season
influenza
vaccin
likewis
urgent
need
develop
effect
vaccin
treatment
potenti
pandem
influenza
virus
although
vaccin
main
method
prevent
influenza
infect
human
antivir
offer
addit
countermeasur
new
rapidlyspread
andor
potenti
pandem
influenza
virus
therapeut
choic
control
influenza
infect
current
limit
two
class
fdaapprov
antivir
target
either
viral
ion
channel
amantadin
rimantadin
sialidas
activ
site
na
oseltamivir
zanamivir
first
inhibit
initi
step
viru
life
cycl
second
inhibit
viru
releas
howev
na
inhibitor
type
antivir
approv
prophylaxi
treatment
ibv
infect
although
data
clinic
trial
shown
oseltamivir
less
effect
ibv
iav
importantli
mutat
viral
genom
lead
influenza
antivir
ineffect
like
case
blocker
longer
recommend
circul
season
influenza
viral
strain
therefor
emerg
drugresist
influenza
variant
increas
concern
control
influenza
infect
signific
need
identif
novel
compound
antivir
properti
influenza
virus
evad
human
preexist
immun
accumul
mutat
antigen
drift
allow
reinfect
individu
previous
expos
natur
infect
vaccin
thu
vaccin
compani
reformul
composit
influenza
vaccin
yearli
ensur
good
match
virus
present
vaccin
season
circul
human
global
influenza
surveil
network
gisn
includ
nation
influenza
center
countri
track
evolut
epidemiolog
influenza
virus
use
collect
data
vaccin
strain
select
process
studi
also
help
understand
viru
evolut
epidemiolog
differ
geograph
area
nation
institut
infecti
diseas
tokyo
japan
basic
degre
immun
induc
one
influenza
strain
effect
anoth
strain
mainli
depend
antigen
differ
viral
strain
influenza
viral
glycoprotein
ha
primari
target
protect
neutral
immun
respons
focu
influenza
viru
surveil
primari
compon
target
current
licens
influenza
vaccin
influenza
vaccin
product
challeng
wait
time
need
identifi
predomin
circul
viru
product
time
need
manufactur
vaccin
nation
influenza
center
perform
viru
isol
certain
sampl
obtain
patient
identifi
circul
virus
determin
virus
grow
effici
cultur
normal
influenza
virus
isol
use
madin
darbi
canin
kidney
mdck
cell
instead
chicken
embryon
egg
higher
isol
rate
especi
iav
strain
report
use
mdck
cell
although
influenza
virus
isol
mammalian
cell
virus
must
gener
embryon
egg
vaccin
manufactur
due
regul
nowaday
vaccin
strain
must
select
almost
month
ahead
influenza
season
use
recommend
strain
includ
vaccin
composit
northern
hemispher
made
februari
allow
time
million
dose
vaccin
produc
time
vaccin
peopl
octobernovemb
allow
influenza
season
prepar
typic
peak
sometim
decemb
march
hand
southern
hemispher
recommend
provid
septemb
vaccin
take
place
marchapril
follow
year
season
influenza
vaccin
must
protect
b
viral
strain
current
circul
human
global
main
goal
influenza
vaccin
protect
infect
diseas
caus
influenza
infect
restrict
viru
transmiss
within
popul
nab
respons
commonli
assess
measur
hemagglutin
inhibit
hai
titer
current
use
serolog
marker
effici
immunolog
respons
vaccin
effect
influenza
vaccin
variabl
usual
higher
children
healthi
adult
age
individu
year
age
lower
effect
observ
recommend
influenza
vaccin
differ
countri
sinc
influenza
vaccin
induc
longlast
antibodi
protect
annual
influenza
vaccin
recommend
nowaday
use
influenza
vaccin
divid
iiv
laiv
kill
viru
vaccin
iiv
gener
administ
intramuscularli
classifi
whole
viru
vaccin
split
vaccin
whole
viru
vaccin
first
develop
influenza
viru
grown
embryon
chicken
egg
subsequ
purifi
concentr
chemic
inactiv
formaldehyd
figur
whole
viru
vaccin
safe
well
toler
efficaci
children
adult
hand
splitviru
vaccin
expos
viral
protein
subvir
element
upon
dissoci
virion
nonion
deterg
treatment
step
influenza
vaccin
us
europ
eggproduc
formaldehydeinactiv
chemic
disrupt
nonion
deterg
purif
unlik
virusbas
vaccin
subunit
influenza
vaccin
consist
purifi
viral
ha
hana
protein
without
viral
compon
subunit
vaccin
produc
egg
viral
protein
prepar
virus
hana
purifi
remov
viral
compon
addit
subunit
vaccin
gener
use
novel
manufactur
technolog
allow
product
larg
quantiti
viral
ha
use
baculoviru
express
system
recombin
dna
technolog
iav
strain
use
vaccin
manufactur
highgrowth
reassort
contain
ha
na
gene
segment
target
strain
backbon
influenza
apuerto
high
growth
viru
influenza
replic
high
titer
egg
cell
also
favor
safeti
profil
human
figur
gener
reassort
virus
egg
coinfect
season
strain
figur
select
appropri
seed
vaccin
virus
made
amplif
presenc
ha
na
nab
figur
select
virus
clone
sequenc
confirm
ibv
vaccin
typic
wildtyp
wt
virus
howev
ibv
reassort
use
wt
ibv
growth
properti
optim
effici
growth
vaccin
product
remain
class
vaccin
consist
liveattenu
influenza
virus
attenu
human
laiv
develop
serial
passag
viru
egg
use
suboptim
condit
temperatur
result
attenu
virus
display
temperaturesensit
ts
coldadapt
ca
attenu
att
phenotyp
grew
c
temperatur
found
lower
respiratori
tract
c
ts
ca
att
phenotyp
restrict
viru
replic
upper
respiratori
track
virus
could
induc
local
protect
immunolog
respons
laiv
avail
us
sinc
administr
intranas
advantag
live
viru
vaccin
compar
inactiv
viru
vaccin
appli
nasal
mucosa
vaccin
induc
local
immun
includ
nab
gener
cellmedi
immun
respons
provid
crossreact
longer
last
immun
respons
laiv
avail
us
sinc
administr
intranas
advantag
live
viru
vaccin
compar
inactiv
viru
vaccin
appli
nasal
mucosa
vaccin
induc
local
immun
includ
nab
gener
cellmedi
immun
respons
provid
crossreact
longer
last
immun
respons
current
laiv
consist
intern
viral
segment
pa
np
ns
attenu
master
donor
viru
mdv
ha
na
viral
segment
select
season
viru
strain
figur
mdv
use
aann
bann
iav
ibv
respect
similar
mdv
iav
mdv
ibv
origin
deriv
serial
passag
parent
wt
viru
isol
success
reduc
temperatur
primari
chicken
kidney
pck
cell
result
ibv
mdv
grow
effici
c
ca
growth
restrict
c
ts
genet
chang
mdv
strain
recent
character
mdv
iav
includ
five
mutat
two
viral
polymeras
np
mdv
ibv
report
contain
two
mutant
amino
acid
np
one
pa
respons
ts
ca
signatur
two
addit
residu
provid
mdv
ibv
attenu
att
phenotyp
although
laiv
approv
clinic
use
date
mechan
attenu
complet
understood
howev
toler
laiv
specif
popul
import
concern
inher
risk
immun
live
virus
thu
laiv
recommend
immunocompromis
patient
asthmat
approv
use
children
two
year
age
moreov
laiv
harbor
differ
ha
na
viral
segment
unequ
safe
immunogen
year
year
viral
ha
na
differ
similar
us
laiv
russia
two
ts
ca
mdv
iav
obtain
use
similar
temperatur
adapt
approach
two
russian
mdv
origin
parent
influenza
strain
similarli
us
mdv
russian
mdv
select
grow
embryon
chicken
egg
lower
c
temperatur
mdv
obtain
passag
c
use
prepar
russian
laiv
use
adult
genet
chang
mdv
identifi
includ
four
mutat
three
viral
protein
nep
second
donor
strain
obtain
total
passag
use
vaccin
children
less
year
age
although
genet
chang
respons
ts
ca
phenotyp
well
character
case
like
iiv
mdv
contain
six
intern
gene
gener
vaccin
strain
combin
season
recommend
ha
na
gene
circul
strain
figur
laiv
gener
either
classic
reassort
egg
previous
describ
iiv
figur
revers
genet
indic
influenza
viru
vaccin
tradit
produc
egg
progress
made
mammalian
cell
cultur
technolog
influenza
vaccin
manufactur
invest
novel
cell
cultur
system
mass
product
influenza
vaccin
without
need
egg
major
current
licens
influenza
vaccin
made
biotechnolog
compani
use
fertil
chicken
eggbas
product
technolog
process
multipl
drawback
form
manufactur
depend
access
embryon
egg
reli
abil
influenza
virus
effici
grow
egg
resourceand
timeintens
process
moreov
risk
egg
contamin
avian
pathogen
microb
repres
risk
product
influenza
vaccin
importantli
case
iav
pandem
egg
suppli
compromis
iiv
one
dose
adult
contain
approxim
ha
viral
ha
three
antigen
ibv
compon
mean
one
egg
dose
vaccin
laiv
share
similar
eggbas
product
process
step
laiv
recov
infect
egg
purifi
concentr
importantli
new
vaccin
product
approach
depend
propag
influenza
virus
egg
eg
cell
cultur
repres
excel
option
increas
influenza
vaccin
product
mammalian
cell
cultur
use
biopharmaceut
industri
product
therapeut
protein
andor
vaccin
fda
approv
cellbas
product
process
influenza
vaccin
manufactur
process
begin
egggrown
vaccin
virus
per
fda
regul
influenza
vaccin
product
use
fdaapprov
mdck
vero
african
green
monkey
kidney
cell
may
eventu
complet
replac
use
egg
product
influenza
vaccin
futur
influenza
vaccin
product
mammalian
cell
line
offer
sever
advantag
eggbas
product
allow
faster
greater
product
capac
improv
avail
substrat
viru
growth
elimin
relianc
suppli
embryon
chicken
egg
addit
cell
cultur
cryopreserv
scale
bioreactor
time
adjuv
shown
enhanc
immun
respons
elicit
antigen
could
use
improv
immunogen
iiv
use
adjuv
could
also
reduc
vaccin
dose
stretch
antigen
vaccin
suppli
current
fdalicens
adjuv
influenza
vaccin
usag
includ
aluminum
salt
alum
squalen
oilinwat
emuls
system
wadman
novarti
glaxosmithklin
howev
current
iiv
contain
type
adjuv
mani
investig
genet
techniqu
gener
recombin
virus
first
develop
dna
virus
base
transfect
cell
plasmid
encod
viral
genom
heterolog
recombin
plasmid
bear
viral
sequenc
viru
genom
helper
viru
initi
genet
approach
dna
virus
follow
manipul
positivesens
rna
viral
genom
transfect
plasmid
dna
rna
transcrib
directli
vitro
plasmid
contain
genom
polioviru
suscept
cell
led
gener
recombin
infecti
polioviru
howev
genom
negativesens
rna
virus
includ
influenza
less
suitabl
molecular
biolog
manipul
comparison
dna
positivesens
rna
virus
sinc
genom
complementari
mrna
orient
therefor
infecti
requir
presenc
vrna
viral
rdrp
initi
replic
cycl
viru
advent
revers
genet
molecular
engin
transform
influenza
field
allow
multipl
question
answer
use
geneticallyengin
recombin
influenza
virus
studi
includ
mechan
viral
genom
replic
gene
transcript
pathogen
virul
virushost
interact
host
rang
transmiss
moreov
technolog
implement
develop
influenza
vaccin
gener
recombin
influenza
virus
express
foreign
protein
vaccin
vector
harbor
report
gene
easili
track
viral
infect
plasmidbas
revers
genet
influenza
viru
allow
simultan
express
viral
compon
involv
viral
genom
replic
gene
transcript
pa
np
eight
negativestrand
vrna
transfect
suscept
cell
togeth
gener
de
novo
recombin
iav
ibv
figur
goal
gener
vrna
vivo
clone
complementari
c
dna
achiev
rna
polymeras
pol
system
influenza
vrna
synthesi
establish
pol
nuclear
enzym
transcrib
ribosom
r
rna
like
influenza
vrna
contain
cap
structur
poli
structur
end
importantli
pol
initi
termin
transcript
defin
promot
termin
sequenc
allow
gener
vrna
without
addit
nucleotid
end
requir
effici
gener
recombin
virus
use
revers
genet
nevertheless
pol
promot
speci
specif
origin
establish
influenza
rescu
human
cell
current
pol
promot
differ
speci
identifi
allow
gener
recombin
influenza
virus
use
revers
genet
techniqu
avian
canin
equin
murin
cell
line
nevertheless
pol
promot
speci
specif
origin
establish
influenza
rescu
human
cell
current
pol
promot
differ
speci
identifi
allow
gener
recombin
influenza
virus
use
revers
genet
techniqu
avian
canin
equin
murin
cell
line
influenza
virus
requir
presenc
eight
vrna
segment
effici
viru
fit
success
product
virion
progeni
initi
descript
influenza
revers
genet
origin
establish
iav
requir
use
plasmid
gener
recombin
influenza
virus
four
polymeras
ii
pol
ii
protein
express
plasmid
encod
viral
rdrp
complex
pa
np
vrnp
reconstitut
eight
pol
idriven
plasmid
express
eight
vrna
segment
howev
later
describ
influenza
virus
requir
presenc
eight
vrna
segment
effici
viru
fit
success
product
virion
progeni
initi
descript
influenza
revers
genet
origin
establish
iav
requir
use
plasmid
gener
recombin
influenza
virus
four
polymeras
ii
pol
ii
protein
express
plasmid
encod
viral
rdrp
complex
pa
np
vrnp
reconstitut
eight
pol
idriven
plasmid
express
eight
vrna
segment
howev
later
describ
eight
ambisens
andor
bidirect
plasmid
need
complet
reconstitut
influenza
virus
figur
eight
plasmidbas
rescu
system
common
method
gener
recombin
influenza
virus
fewer
plasmid
requir
eightplasmid
approach
success
initi
twelveplasmid
revers
genet
techniqu
core
eightplasmid
rescu
system
plasmid
contain
ambisens
cassett
includ
rna
pol
andor
ii
sequenc
drive
transcript
vrna
pol
protein
pol
ii
express
viral
cdna
figur
use
similar
technolog
revers
genet
techniqu
allow
recoveri
ibv
entir
ambisens
plasmid
iav
ibv
revers
genet
techniqu
well
establish
commonli
use
multipl
research
laboratori
differ
research
purpos
influenza
revers
genet
techniqu
import
effect
expand
knowledg
molecular
biolog
pathogenesi
influenza
virus
allow
research
answer
import
question
biolog
iav
ibv
possibl
use
convent
virolog
biochem
procedur
scientist
mutat
specif
nucleotid
influenza
viral
genom
elucid
natur
regulatori
sequenc
contribut
specif
amino
acid
function
influenza
viral
protein
instanc
revers
genet
technolog
enabl
identif
character
cisact
element
requir
viru
cell
entri
uncoat
genom
replic
gene
transcript
encapsid
packag
viral
releas
moreov
engin
viral
vector
suitabl
express
foreign
protein
infect
cell
multipl
recombin
influenza
virus
harbor
report
fluoresc
andor
luminesc
gene
gener
use
identifi
antivir
nab
vitro
andor
vivo
final
revers
genet
allow
creation
singlecycl
infecti
iav
sciiav
restrict
one
cycl
replic
parent
cell
line
howev
complement
cell
line
sciiav
replic
effici
level
compar
wt
form
influenza
virus
highli
virul
iav
potenti
pose
greater
human
threat
mani
biosafeti
level
bsl
pathogen
effici
transmiss
limit
therapeut
option
tradit
immunolog
approach
eg
hai
microneutr
assay
identifi
presenc
iav
nab
reli
manipul
live
form
virus
need
use
special
bsl
condit
thu
novel
approach
allow
detect
viral
nab
without
use
live
form
iav
highli
contain
bsl
laboratori
would
facilit
serolog
assay
regard
safeti
profil
sciiav
repres
excel
altern
identifi
new
antivir
andor
nab
moreov
sever
sciiav
shown
repres
excel
option
implement
safe
immunogen
protect
vaccin
andor
vaccin
vector
influenza
plasmidbas
revers
genet
repres
better
altern
circumv
process
gener
reassort
viru
coinfect
chicken
embryon
egg
gener
influenza
vaccin
figur
moreov
gener
recombin
influenza
virus
use
plasmidbas
revers
genet
approach
simpl
well
establish
current
use
sever
laboratori
around
world
figur
briefli
eightambisens
plasmid
cotransfect
suscept
fdaapprov
cell
viabl
viru
recov
tissu
cultur
supernat
amplifi
either
embryon
egg
fdaapprov
vaccin
product
cell
figur
mani
year
iiv
produc
reassort
egg
figur
howev
strain
desir
genotyp
six
intern
gene
highgrowth
viru
ha
na
glycoprotein
season
influenza
viru
could
produc
easili
quickli
implement
revers
genet
approach
process
would
overcom
need
chicken
embryon
egg
gener
desir
reassort
viru
therefor
minim
time
associ
select
process
reassort
iiv
figur
moreov
improv
surveil
well
de
novo
gene
synthesi
product
ha
na
viral
segment
select
strain
could
reduc
consider
time
vaccin
product
although
influenza
revers
genet
could
use
product
vaccin
seed
strain
date
possibl
predict
gene
segment
constel
requir
effici
growth
differ
vaccin
virus
moreov
time
produc
vaccin
virus
use
revers
genet
versu
time
need
gener
use
classic
reassort
approach
could
major
consider
cost
effect
vaccin
product
manufactur
thu
tradit
viral
reassort
remain
prefer
allow
gener
number
divers
gene
combin
order
select
recombin
virus
better
fit
last
decad
consider
improv
accomplish
develop
influenza
vaccin
howev
novel
approach
increas
effect
season
influenza
vaccin
need
revers
genet
technolog
proven
valuabl
tool
develop
reassort
strain
product
laiv
candid
figur
current
seed
virus
contain
six
gene
segment
mdv
aann
ha
na
select
season
viru
quickli
gener
use
revers
genet
system
figur
ha
na
select
season
influenza
virus
amplifi
rtpcr
quickli
chemic
synthet
clone
ambisens
plasmid
use
viru
rescu
technolog
could
speed
develop
new
laiv
bypass
need
isol
exact
viru
reassort
egg
figur
best
way
combat
influenza
viru
infect
prevent
thu
urgent
need
exist
develop
novel
effect
influenza
vaccin
plasmidbas
revers
genet
technolog
allow
engin
recombin
influenza
virus
contain
singl
multipl
mutat
viral
genom
potenti
implement
novel
improv
vaccin
approach
fact
sever
novel
vaccin
candid
develop
promis
result
anim
model
experiment
review
discuss
abil
hijack
host
innat
immun
ifni
respons
varieti
potenti
vaccin
strategi
develop
base
use
modifi
protein
mean
viru
attenu
equin
swine
avian
canin
human
iav
partial
truncat
delet
viral
protein
attenu
vitro
vivo
importantli
recombin
iav
induc
protect
immun
respons
upon
singl
intranas
vaccin
mice
hors
pig
bird
macaqu
therefor
repres
excel
laiv
candid
prevent
iav
infect
addit
similar
approach
employ
develop
attenu
ibv
similar
result
mice
inocul
delet
mutant
elicit
antibodi
respons
show
protect
wt
viru
challeng
thu
influenza
b
virus
repres
excel
candid
safe
immunogen
protect
laiv
multipl
viru
strain
differ
anim
model
genet
code
anim
encod
differ
amino
acid
aa
use
codon
degeneraci
genet
code
allow
amino
acid
except
tryptophan
w
methionin
encod
one
synonym
codon
virus
includ
influenza
reli
host
cell
translat
machineri
synthes
viral
protein
format
infecti
viru
progeni
evolutionari
consequ
virus
modifi
codon
usag
accord
host
infect
experiment
protein
synthesi
downregul
synthet
deoptim
codon
usag
gene
gener
recombin
virus
contain
gene
deoptim
codon
feasibl
level
attenu
depend
viral
gene
target
number
codon
chang
made
codon
deoptim
process
influenza
virus
mani
region
viral
genom
alter
import
role
viral
replic
transcript
eg
ncr
packag
eg
packag
signal
presenc
multipl
overlap
orf
eg
segment
etc
date
recombin
iav
attenu
use
codonpair
codon
bia
deoptim
approach
decreas
express
level
viral
ha
np
na
ha
nep
gener
importantli
influenza
virus
gener
codon
deoptim
show
similar
viral
replic
kinet
wt
viru
mdck
cell
import
effect
use
vaccin
product
howev
date
abil
recombin
iav
contain
codonpair
codon
bia
deoptim
viral
segment
replic
egg
yet
evalu
importantli
codon
deoptim
iav
attenu
mice
abl
provid
upon
singl
immun
dose
protect
lethal
challeng
wt
form
viru
show
laiv
safe
immunogen
protect
howev
mice
accur
reflect
viru
pathogenesi
immunolog
respons
seen
human
codon
usag
bia
human
therefor
studi
aim
demonstr
safeti
immunogen
protect
efficaci
codon
deoptim
recombin
iav
wellestablish
anim
model
influenza
eg
guinea
pig
ferret
nonhuman
primat
could
lead
implement
laiv
futur
vaccin
promis
approach
develop
laiv
relat
use
sciiav
sciiav
base
safeti
profil
abil
elicit
protect
humor
cellular
respons
protect
effect
repres
feasibl
altern
current
influenza
vaccin
treatment
influenza
viral
infect
howev
date
singlecycl
infecti
ibv
sciibv
report
deliv
intranas
sciiav
shown
safe
mous
model
influenza
infect
without
sign
ill
mortal
moreov
similar
current
laiv
intranas
immun
singl
dose
sciiav
elicit
local
mucos
immun
respons
recruit
influenzaspecif
tcell
lung
vaccin
anim
latest
main
contributor
immun
challeng
heterolog
influenza
virus
importantli
sciiav
protect
mice
lethal
influenza
viru
challeng
moreov
similar
safeti
immunogen
protect
efficaci
sciiav
observ
ferret
vaccin
pig
sciiav
also
shown
immunogen
protect
challeng
swine
influenza
virus
moreov
sciiav
express
foreign
gene
repres
excel
option
implement
bival
vaccin
instanc
sciiav
express
surfac
protein
pspa
streptococcu
pneumonia
hemagglutininneuraminidas
hn
protein
fusion
f
protein
respiratori
syncyti
viru
rsv
abl
induc
ab
foreign
polypeptid
reduc
viral
load
heterolog
pathogen
retain
abil
protect
challeng
iav
worth
indic
vaccin
purpos
import
consid
influenza
viral
gene
replac
sinc
shown
sciiav
replic
requir
protect
although
substitut
polymeras
pa
segment
may
allow
insert
larger
foreign
gene
remov
viral
polymeras
sciiav
limit
abil
express
polymeras
singlecycl
round
infect
decreas
total
viral
antigen
thu
limit
protect
efficaci
thu
sciiav
viral
ha
na
remov
abl
confer
upon
singl
immun
protect
lethal
challeng
influenza
contrari
singl
dose
sciiav
viral
remov
efficaci
inactiv
viru
worth
note
sciiav
combin
advantag
better
immunogen
properti
laiv
safeti
profil
iiv
circumv
disadvantag
safeti
laiv
poor
immunogen
iiv
current
influenza
vaccin
approach
sciiav
shown
safe
immunogen
protect
lethal
challeng
wildtyp
form
iav
anim
studi
human
trial
yet
perform
recent
rearrang
influenza
viru
genom
shown
great
potenti
develop
improv
laiv
influenza
viru
well
vaccin
vector
pathogen
avian
influenza
viru
subtyp
pandem
potenti
howev
iiv
induc
limit
adapt
immun
respons
case
laiv
safeti
concern
possibl
reassort
viral
segment
laiv
circul
strain
overcom
concern
bival
laiv
influenza
aguinea
fowlhong
gener
use
viral
genom
rearrang
end
nep
remov
ns
viral
segment
viru
substitut
ha
viru
ha
separ
footandmouth
diseas
viru
fmdv
autocleavag
site
allow
colinear
express
viral
protein
nep
clone
downstrain
segment
separ
anoth
fmdv
autocleavag
site
rearrang
viru
express
ha
abl
provid
complet
protect
challeng
also
potenti
pandem
iav
reassort
viru
mice
ferret
segment
ns
iav
use
altern
splice
mechan
express
two
differ
viral
protein
viral
segment
recent
gener
recombin
influenza
apuerto
virus
contain
modifi
andor
ns
segment
overlap
orf
viral
protein
segment
andor
nep
protein
ns
segment
separ
porcin
teschoviru
autocleavag
site
recombin
virus
rearrang
segment
affect
impair
replic
vitro
nonpermiss
temperatur
c
respect
wherea
high
viral
titer
obtain
permiss
low
temperatur
c
notabl
virus
contain
split
segment
highli
attenu
vivo
abl
confer
upon
singl
immun
dose
complet
protect
lethal
homolog
challeng
wildtyp
importantli
virus
reorgan
segment
abl
confer
better
protect
temperaturesensit
laiv
viru
studi
demonstr
rearrang
influenza
viral
genom
use
gener
safe
immunogen
protect
laiv
current
influenza
vaccin
induc
immun
influenza
viru
strainspecif
ha
antigen
effect
new
pandem
virus
given
ha
highli
suscept
frequent
chang
antigen
drift
shift
overcom
drawback
differ
approach
aim
develop
univers
influenza
vaccin
abl
induc
crossprotect
broadli
neutral
immun
conserv
viral
antigen
ectodomain
ha
stalk
domain
na
explor
antigen
linear
peptid
well
conserv
across
iav
strain
although
mechan
immun
unclear
protect
antibodi
observ
multipl
anim
model
includ
mice
ferret
primat
howev
conserv
antigen
target
need
present
carrier
system
conjug
adjuv
molecul
promis
result
obtain
viruslik
particl
vlp
morpholog
similar
viru
present
surfac
protein
highli
immunogen
form
vlp
contain
viral
genom
consid
safer
viral
vaccin
yet
still
induc
strong
humor
cellular
immun
respons
vlp
commonli
made
express
ha
na
although
ha
na
alon
may
suffici
vlp
product
revers
genet
approach
gener
recombin
virus
includ
influenza
describ
repres
famili
member
negativesens
singlestrand
rna
virus
plasmidbas
revers
genet
method
provid
scientist
uniqu
opportun
studi
differ
aspect
biolog
pathogenesi
virus
vitro
vivo
well
gener
attenu
form
use
vaccin
review
discuss
use
revers
genet
gener
influenza
vaccin
special
focu
laiv
gener
laiv
highli
immunogen
immun
usual
induc
faster
substanti
higher
level
system
local
mucos
antibodi
tcell
respons
provid
better
protect
inactiv
counterpart
prevent
influenza
viru
infect
requir
season
vaccin
identif
correct
viru
subtyp
includ
vaccin
leav
littl
time
vaccin
develop
scale
distribut
although
influenza
vaccin
work
well
year
new
viral
variant
emerg
strain
includ
vaccin
select
efficaci
vaccin
would
suboptim
new
variant
strain
usual
result
decreas
efficaci
vaccin
revers
genet
approach
also
allow
develop
liveattenu
virus
could
implement
near
futur
laiv
new
advanc
revers
genet
approach
reduc
potenti
time
recoveri
product
month
week
repres
excel
altern
rapid
develop
implement
laiv
treatment
season
potenti
pandem
influenza
strain
acknowledg
influenza
viru
research
lui
aitor
nogal
laboratori
partial
fund
nation
institut
allergi
infecti
diseas
niaid
center
excel
influenza
research
surveil
ceir
author
declar
conflict
interest
